Last edition
News about "Acesion Pharma "
Acesion Pharma Begins Phase-II Trial of AP31969 in Atrial Fibrillation
The Phase-II study of AP31969 by Acesion Pharma will evaluate the efficacy and safety of AP31969, a first-in-class oral SK ion channel inhibitor, in reducing atrial fibrillation burden using continuous cardiac rhythm monitoring.
Acesion Pharma | 08/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members